Cancer Therapy & Oncology
International Journal
ISSN: 2473-554X

Juniper Publishers
key to the Researchers

Review Article
Volume 14 Issue 4 - July 2019
DOI: 10.19080/CTOIJ.2019.14.555891

Cancer Ther Oncol Int J

Treatment of Lung Cancer

Rana Khalid Iqbal*, Farwa Mumtaz and Asifa Akram

Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, 60800- Multan-Pakistan

Submission: : June 21, 2019; **Published:** July 22, 2019

***Correspondence Author:** Rana Khalid Iqbal, Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, 60800- Multan, Pakistan

Abstract

Lung cancer treatment is the deadliest cancer in both men and women. It is the abnormality of non-dividing cells. It is mostly caused by smoking. Treatments are available on the bases of staging of cancer in an individual. We have explained some different treatment of lung cancer including chemotherapy, radiotherapy and lobectomy means, surgery and immunotherapy etc. ratio of cancer patients is increasing day by day. Many techniques have been proven useful for the cancer disease.

Keywords: Chemotherapy; Radiobiology; NSCLC (non-small-cell lung cancer)

Introduction

Lung cancer is the collection of disease with both tissue and molecular level [1]. Treatment will be based on the consequence of tumours on molecular and histological level related to the stage of diagnosis and present condition of disease [2]. Chemotherapy, radio-therapy and all other easing care have role in the control of disease [3] Management judicial were held in the presence of all medicines including the respiratory physician, clinical oncologic, radiologist, surgeons and palliative care team members. Cancer is treated by chemotherapy [4]. Our primary treatment is Radiation therapy. It can decrease the risk of spreading the disease to the other parts of the body [5]. Sometime Lung cancer is not cured surgically is just relay on person's health. It is treated through chemotherapy combinated by radio-therapy [6]. Thus some people wholly cured and some are not. The survival rate is five year but in case of excluding treatment it hold the life for just 2-4 months, and in case of treatment it I 6-12 months [7]. It is noted that the molecular therapy involves the Tyrosine kinase inhibitors (TKI) and anaplastic lymphoma kinase (ALK) inhibitors are considered as growth receptors that play role in the tumour harbouring by genetic alteration.

Pathological Mechanism of Thrombus Formation

Lobectomy is the most reliable radical treatment of primary lung cancer.it involves pulmonary vessels [8] many difficulties and complications arrived after lobectomy treatment including bleeding, air leak, infection, chylothorax, and heart problems [9]. Cerebral thromboembolism is the life-threatening problem in early postoperative time. It occurs mostly at 0.2-1.2% of surgical cases of lung cancer [10]. Cerebral thromboembolism appears after lobectomy. Atherogenicity also is the reason of cerebral embolism. But we will not discuss it here [11] (Figure 1).



Figure 1: Mechanism of cerebral embolism after lobectomy of lung cancer [4].

Development of Thrombectomy

It had been most novel reliable therapy for cerebellum ischiatic diseases, though they acute stage is treated through pharmacotherapeutic way i.e. involve tissue activator [12]. Albeit

it has been necessary to know whether the ischiatic stroke was cardiogenic to the pharmacotherapeutic application or not [13].

Radiobiological Treatment

PET molecular imaging has been proven a great detectors of malignant cells, we can diagnose and treat the cancer through different techniques of radiobiology using isotopes i.e. gallium-68 that enable the signal detection through PET/MRI [14]. Hopefully these approaches should gather the useful therapies for patients in future [15].

Chemotherapeutic Treatment

Recent Mata-analysis have been showing the advantages of chemotherapy after surgical carve simultaneously an increasing survival rate of about 4% in 5 years. The benefit has been regardless on chemotherapy base or morbid class [16].

Invasive surgery in Non-small cell

Normalization of VATS

Two forms of VATS are being names as 'hybrid' and 'complete' till not have been normalized [14]. Surgeon would make a small thoracotomy and use the all direct imaging or video managing from gashed site directly [11] Cancer and leukaemia were the first approaches that were examine by these two types of VATS lobectomy in lung cancer 2007 [17]. Some great scientists gave some definitions of VATS.

i. Incision through a maximum length about 8cm for taking a specimen.

ii. Normative node sampling

iii. Disruption

Conclusion

Thrombus pathology had been increases due to the useful advantages e.g. the removing of many thrombotic specimens. Radiolabelled therapy is the greater therapy for diagnostic and detection of cancer cells. It is cleared that the types of VATS have been proven useful techniques for the lung cancer that would be sited as substituted not competitive with each other.

References

1. Turan I, Demir S, Kilinc K, Burnaz NA, Yaman SO, et al. (2017) Antiproliferative and apoptotic effect of Morus nigra extract on human prostate cancer cells. Saudi Pharm J 25(2): 241–248.
2. U Khalid, C Vi, J Henri, J Macdonald, P Eu, et al. (2018) Radiolabelled Aptamers for Theranostic Treatment of Cancer. Pharmaceuticals (Basel) 12(1).
3. S Demir, I Turan, R Aliyazicioglu, S Ozer (2018) Primula vulgaris extract induces cell cycle arrest and apoptosis in human cervix cancer cells. J Pharm Anal vol 8(5): 307–311.
4. H Hashimoto, G Usui, Y Tsugeno, K Sugita, G Amori (2019) Cerebral Thromboembolism after Lobectomy for Lung Cancer : Pathological Diagnosis and Mechanism of Thrombus Formation. Cancers (Basel) 11(4).
5. G Anandappa (2016) Management of lung cancer Key points," Medicine (Baltimore). 44(4): 244–248.
6. Ghagane SC, Puranik SI, Kumbar VM, Nerli RB, Jalalpure SS, et al. (2017) In vitro antioxidant and anticancer activity of Leea indica leaf extracts on human prostate cancer cell lines. Integr Med Res 6(1): 79–87.
7. F Petrelli, M Maltese, G Tomasello, B Conti, K Borgonovo et al. (2018) Clinical and Molecular Predictors of PD-L1 Expression in Non e Small-Cell Lung Cancer: Systematic Review and Meta-analysis. Clin Lung Cancer19(4): 315–322.
8. M Reck, DF Heigener, T Mok, J Soria, KF Rabe (2013) Lung Cancer 1 Management of non-small-cell lung cancer : recent developments. Lancet 382(9893): 709–719.
9. Ghanem S, El Bitar S, Hossri S, Weerasinghe C, Atallah JP (2017) What we know about surgical therapy in early- stage non-small-cell lung cancer : a guide for the medical oncologist. Cancer Manag Res 9: 267-278.
10. Casal-Mouriño A, Valdés L, Barros-Dios JM, Ruano-Ravina A (2019) Lung cancer survival among never smokers. Cancer Lett., vol. 451, no. February, pp. 142–149.
11. SC Ghagane, SI Puranik, RB Nerli, MB Hiremath (2017) Evaluation of in vitro antioxidant and anticancer activity of Allophylus cobbe leaf extracts on DU-145 and PC-3 human prostate cancer cell lines. Cytotechnology69(1): 167–177.
12. C Gridelli, M Aapro, A Ardizzoni, L Balducci, F De Marinis, K Kelly, et al. (2019) Treatment of Advanced Non – Small-Cell Lung Cancer in the Elderly : Results of an International Expert Panel J Clin Oncol 23(13): 3125–3137.
13. H Nomori, T Mori, K Ikeda, K Yoshimoto (2009) Segmentectomy for selected cT1N0M0 non – small cell lung cancer : A prospective study at a single institute. J Thorac Cardiovasc Surg 144(1): 87-93.
14. Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S (2012) Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection. J Thorac Cardiovasc Surg vol 144(6): 1365–1371.
15. A Baisi, M De Simone, U Cioffi, F Raveglia (1997) Should pulmonary lobectomy be replaced by sublobar resection in patients with stage I non-small cell lung cancer? J Thorac Cardiovasc Surg 147(6): 1997–1998.
16. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y (2016) Recent Advances in Targetable Therapeutics in Metastatic non-Squamous nSCLC. Front Oncol 6: 112.
17. Altorki NK, Yip R·Hanaoka T, Bauer T, Aye R (2014) Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg 147(2): 754–764.

How to cite this article: Rana Khalid Iqbal, Farwa Mumtaz, Asifa Akram. Treatment of Lung Cancer. Canc Therapy & Oncol Int J. 2019; 14(4): 555891. DOI: 10.19080/CTOIJ.2019.14.555891

DOI: 10.19080/CTOIJ.2019.14.555891

How to cite this article: Rana Khalid Iqbal, Farwa Mumtaz, Asifa Akram. Treatment of Lung Cancer. Canc Therapy & Oncol Int J. 2019; 14(4): 555891. DOI: 10.19080/CTOIJ.2019.14.555891